These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2737223)

  • 1. Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung. EORTC Lung Cancer Cooperative Group.
    Anderson G; Clavel M; Smyth J; Giaccone G; Gracia M; Planting AS; Dalesio O; Kirkpatrick A; McVie G
    Eur J Cancer Clin Oncol; 1989 May; 25(5):909-10. PubMed ID: 2737223
    [No Abstract]   [Full Text] [Related]  

  • 2. 2-Methyl-9-hydroxyellipticinium acetate (ellipticinium) in the treatment of lymphomas. Preliminary results of a phase II study.
    Tura S; Mandelli F; Mazza P; Cimino G; Anselmo AP; Amadori S
    Chemioterapia; 1984 Apr; 3(2):79-82. PubMed ID: 6532540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137).
    Paoletti C; Le Pecq JB; Dat-Xuong N; Juret P; Garnier H; Amiel JL; Rouesse J
    Recent Results Cancer Res; 1980; 74():107-23. PubMed ID: 7003658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [2 new antineoplastic derivatives: 9-hydroxy-2-methyl-ellipticinium (acetate) and 9-hydroxy-2,6-dimethyl-ellipticinium (chloride). Effect on mouse L 1210 leukemia].
    Le Pecq JB; Gosse C; Nguyen-Dat-Xuong ; Paoletti C
    C R Acad Hebd Seances Acad Sci D; 1975 Nov; 281(18):1365-7. PubMed ID: 815025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast.
    Sternberg CN; Yagoda A; Casper E; Scoppetuolo M; Scher HI
    Anticancer Res; 1985; 5(4):415-7. PubMed ID: 4037737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elliptinium: phase II study in advanced measurable breast cancer.
    Treat J; Greenspan A; Rahman A; McCabe MS; Byrne PJ
    Invest New Drugs; 1989 Jul; 7(2-3):231-4. PubMed ID: 2793378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elliptinium, a DNA intercalating agent with broad antitumor activity in a human tumor cloning system.
    Arteaga CL; Kisner DL; Goodman A; von Hoff DD
    Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1621-6. PubMed ID: 3428332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of 9-hydroxy-2N-methylellipticinium acetate.
    Clarysse A; Brugarolas A; Siegenthaler P; Abele R; Cavalli F; de Jager R; Renard G; Rozencweig M; Hansen HH
    Eur J Cancer Clin Oncol; 1984 Feb; 20(2):243-7. PubMed ID: 6538489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary trial of 9-hydroxy-2-methyl ellipticinium (NSC 264--137) in advanced human cancers.
    Juret P; Tanguy A; Girard A; Le Talaer JY; Abbatucci JS; Dat-Xuong N; Le Pecq JB; Paoletti C
    Eur J Cancer (1965); 1978 Feb; 14(2):205-6. PubMed ID: 342255
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of metastatic renal cancer in adults with elliptinium acetate].
    Amiel JL; Rouessé J; Droz JP; Caille P; Travagli JP; Théodore C; Le Chevalier T; Ducret JP; Bidart M; Garnier HS
    Presse Med; 1984 Jun; 13(25):1555-7. PubMed ID: 6234539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxy-9-methyl-2-Ellipticinium (NSC 264-137) in 52 cases of osseous metastases from breast cancer.
    Juret P; Le Talaer Y; Couette JE; Delozier T
    Eur J Cancer (1965); 1980; Suppl 1():277-9. PubMed ID: 7032940
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II trial with high-dose elliptinium acetate in metastatic renal cell carcinoma.
    Piot G; Droz JP; Theodore C; Ghosn M; Rouëssé J; Amiel JL
    Oncology; 1988; 45(5):371-2. PubMed ID: 3412745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicochemical and pharmacological properties of the antitumor ellipticine derivative 2-(diethylamino-2-ethyl)9-hydroxy ellipticinium-chloride, HCl.
    Auclair C; Pierre A; Voisin E; Pepin O; Cros S; Colas C; Saucier JM; Verschuere B; Gros P; Paoletti C
    Cancer Res; 1987 Dec; 47(23):6254-61. PubMed ID: 3677074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of elliptinium in advanced renal cell carcinoma.
    Caillé P; Mondesir JM; Droz JP; Kerbrat P; Goodman A; Ducret JP; Theodore C; Spielman M; Rouëssé J; Amiel JL
    Cancer Treat Rep; 1985; 69(7-8):901-2. PubMed ID: 4016798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hydroxy 9-methyl 2-ellipticinium acetate (NSC 264-137). Toxicologic study and therapeutic effect in 100 cancers (author's transl)].
    Juret P; Tanguy A; Girard A; Le Talaer JY; Abbatucci JS; Dat-Yuong ; Le Pecq JB; Paoletti C
    Nouv Presse Med; 1979 Apr; 8(18):1495-8. PubMed ID: 471724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5-year experience.
    Juret P; Heron JF; Couette JE; Delozier T; Le Talaer JY
    Cancer Treat Rep; 1982 Nov; 66(11):1909-16. PubMed ID: 7139636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elliptinium acetate in metastatic breast cancer--a phase II study.
    Buzdar AU; Hortobagyi GN; Esparza LT; Holmes FA; Ro JS; Fraschini G; Lichtiger B
    Oncology; 1990; 47(2):101-4. PubMed ID: 2314820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of elliptinium (2-N-methyl-9-hydroxyellipticinium).
    Einzig AI; Gralla RJ; Leyland-Jones BR; Kelsen DP; Cibas I; Lewis E; Greenberg E
    Cancer Invest; 1985; 3(3):235-41. PubMed ID: 4005651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Failure of elliptinium acetate in the treatment of unresectable hepatocarcinoma (phase II trial)].
    Rougier P; Ychou M; Droz JP
    Bull Cancer; 1988; 75(10):979-81. PubMed ID: 2851337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hydroxy-9-methyl-2-ellipticinium (NSC 264-137) for osseous metastases from breast cancer. A 4 year experience (author's transl)].
    Juret P; Couette JE; Delozier T; Le Talaer JY
    Bull Cancer; 1981; 68(3):224-31. PubMed ID: 7039729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.